FDA
-
-
-
-
-
-
-
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
-
-
-
-
-
-
-
Climb Bio raises $110 million in private placement
-
-
-
-
-
-
-
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
-
-
-
-
-
-
-
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
-
-
-
-
-
-
-
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
-
-
-
-
-
-
-
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
-
-
-
-
-
-
-
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
-
327,775 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

